Prana appoints US analyst to board
Thursday, 25 March, 2004
Melbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.
Most recently, Alsenas managed a hedge fund with an emphasis on biotechnology for ING Investment Management, New York.
"[Alsenas] is held in high regard in the international biotech sector and possesses an extensive knowledge of the industry in which Prana operates. Hi understanding of, and fundamental belief in, our technology and business strategy will help to shape Prana's future," said Prana CEO Geoffrey Kempler.
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
